Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?

Liver transplantation (LT) is one of the leading curative therapies for hepatocellular carcinoma (HCC). Despite recent optimization of transplant selection criteria, including alpha-feto protein, HCC recurrence after LT is still the leading cause of death in these patients. During the last decades,...

Descripción completa

Detalles Bibliográficos
Autores principales: Piñero, Federico, Thompson, Marcos, Marín, Juan Ignacio, Silva, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Opinion Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708877/
https://www.ncbi.nlm.nih.gov/pubmed/33312891
http://dx.doi.org/10.5500/wjt.v10.i11.297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708877/
https://www.ncbi.nlm.nih.gov/pubmed/33312891
http://dx.doi.org/10.5500/wjt.v10.i11.297

Ejemplares similares